Device Trial Radar · NCT06141824
Performance Evaluation of the Lucira COVID-19 & Flu Test
Last checked: Nov 21, 2026Latest source record: Mar 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,361
Actual
Start
Oct 11, 2022
Primary completion
Feb 16, 2023
Study completion Feb 16, 2023
Sponsor
- Lead sponsor
- Lucira Health IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 21, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Lucira COVID-19\& Flu Test is a single use (disposable) RT-LAMP test kit intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B viral RNA in anterior nasal swab specimens. The test consists of a nasal swab, a sample vial the nasal swab sample is placed in the sample vial, containing the sample buffer, and the test unit, which detects whether SARS-CoV-2, Influenza A, and Influenza B virus is present within the specimen during an acute infection. The Lucira test uses a proprietary, molecular based process to detect the presence of SARS-CoV-2, Influenza A, or Influenza B virus. The purpose of this study is to investigate the Lucira COVID-19 \& Flu Test for the in vitro qualitative detection and differentiation of RNA from SARS-CoV-2, Influenza A, and Influenza B in nasal swab specimens from patients suspected of COVID-19 or Influenza A or Influenza B. The primary objective is to test at least 1000 self-collected nasal swab samples and to confirm the Lucira COVID-19 \& Flu Test provides similar accuracy to a high complexity lab molecular diagnostic RT-PCR assay(s) with known high sensitivity for detecting SARS-CoV-2, Influenza A, and Influenza B virus.
Conditions
- COVID-19
- Influenza
Interventions
Lucira COVID-19 & Flu TestDevice
The Lucira COVID-19 \& Flu Test is a rapid, single-use, molecular test for the qualitative detection and discrimination of SARS-CoV-2, Influenza A, and Influenza B viral RNA in nasal swab samples.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmation That the Lucira COVID-19 & Flu Test Provides Similar Performance to a High Complexity Lab Molecular Diagnostic RT-PCR Assay(s) With Known High SensitivityTime frame: Day 1
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Cullman Clinical Trials
Cullman, Alabama
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.